{"name":"Aurinia Pharmaceuticals","slug":"aurinia-pharmaceuticals","ticker":"AUPH","exchange":"NASDAQ","domain":"auriniapharma.com","description":"Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.","hq":"Victoria, British Columbia, Canada","founded":0,"employees":"128","ceo":"","sector":"Autoimmune / Nephrology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":15.93,"stockChange":-0.1,"stockChangePercent":-0.62,"marketCap":"$2.0B","metrics":{"revenue":298295008,"revenueGrowth":24.4,"grossMargin":78.3,"rdSpend":0,"netIncome":298212992,"cash":378524000,"dividendYield":0,"peRatio":7.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Voclosporin High Dose","genericName":"Voclosporin High Dose","slug":"voclosporin-high-dose","indication":"Other","status":"phase_2"},{"name":"Voclosporin Low Dose","genericName":"Voclosporin Low Dose","slug":"voclosporin-low-dose","indication":"Other","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LUPKYNIS","genericName":"LUPKYNIS","slug":"lupkynis","indication":"Lupus nephritis (Class III or IV)","status":"marketed"}]}],"pipeline":[{"name":"LUPKYNIS","genericName":"LUPKYNIS","slug":"lupkynis","phase":"marketed","mechanism":"LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation.","indications":["Lupus nephritis (Class III or IV)"],"catalyst":""},{"name":"Voclosporin High Dose","genericName":"Voclosporin High Dose","slug":"voclosporin-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Voclosporin Low Dose","genericName":"Voclosporin Low Dose","slug":"voclosporin-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_2":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":283055000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":283055000},{"period":"2024-12-31","value":235133000},{"period":"2023-12-31","value":175513000},{"period":"2022-12-31","value":134030000}],"grossProfit":250390000,"grossProfitHistory":[{"period":"2025-12-31","value":250390000},{"period":"2024-12-31","value":206885000},{"period":"2023-12-31","value":161365000},{"period":"2022-12-31","value":128366000}],"rdSpend":32505000,"rdSpendHistory":[{"period":"2025-12-31","value":32505000},{"period":"2024-12-31","value":20785000},{"period":"2023-12-31","value":49641000},{"period":"2022-12-31","value":44988000}],"sgaSpend":101794000,"operatingIncome":106561000,"operatingIncomeHistory":[{"period":"2025-12-31","value":106561000},{"period":"2024-12-31","value":18419000},{"period":"2023-12-31","value":-91691000},{"period":"2022-12-31","value":-111470000}],"netIncome":287202000,"netIncomeHistory":[{"period":"2025-12-31","value":287202000},{"period":"2024-12-31","value":5752000},{"period":"2023-12-31","value":-78020000},{"period":"2022-12-31","value":-108180000}],"eps":2.07,"epsHistory":[{"period":"2025-12-31","value":2.07},{"period":"2024-12-31","value":0.04},{"period":"2023-12-31","value":-0.54},{"period":"2022-12-31","value":-0.76}],"cash":80213000,"cashHistory":[{"period":"2025-12-31","value":80213000},{"period":"2024-12-31","value":83433000},{"period":"2023-12-31","value":48875000},{"period":"2022-12-31","value":94172000}],"totalAssets":751587000,"totalLiabilities":170256000,"totalDebt":74812000,"equity":581331000,"operatingCashflow":135658000,"operatingCashflowHistory":[{"period":"2025-12-31","value":135658000},{"period":"2024-12-31","value":44388000},{"period":"2023-12-31","value":-33461000},{"period":"2022-12-31","value":-79529000}],"capex":-252000,"capexHistory":[{"period":"2025-12-31","value":-252000},{"period":"2024-12-31","value":-281000},{"period":"2023-12-31","value":-718000},{"period":"2022-12-31","value":-292000}],"freeCashflow":135406000,"dividendsPaid":null,"buybacks":-98156000,"employees":128,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":22029000,"ebit":44937000,"ebitda":49753000,"period":"2026-03-31","revenue":77705000,"epsBasic":0.26,"netIncome":34355000,"rdExpense":7470000,"epsDiluted":0.25,"grossProfit":71200000,"operatingIncome":41422000},{"sga":29255000,"ebit":36737000,"ebitda":41601000,"period":"2025-12-31","revenue":77114000,"epsBasic":1.6,"netIncome":210794000,"rdExpense":10895000,"epsDiluted":1.53,"grossProfit":68315000,"operatingIncome":33239000},{"sga":26182000,"ebit":33061000,"ebitda":37926000,"period":"2025-09-30","revenue":73468000,"epsBasic":0.24,"netIncome":31551000,"rdExpense":8435000,"epsDiluted":0.23,"grossProfit":65291000,"operatingIncome":29745000},{"sga":26018000,"ebit":23273000,"ebitda":28137000,"period":"2025-06-30","revenue":70008000,"epsBasic":0.16,"netIncome":21513000,"rdExpense":7432000,"epsDiluted":0.16,"grossProfit":62893000,"operatingIncome":20197000},{"sga":20339000,"ebit":25416000,"ebitda":30272000,"period":"2025-03-31","revenue":62465000,"epsBasic":0.17,"netIncome":23344000,"rdExpense":5743000,"epsDiluted":0.16,"grossProfit":53891000,"operatingIncome":23380000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":15.93,"previousClose":16.03,"fiftyTwoWeekHigh":16.88,"fiftyTwoWeekLow":7.29,"fiftyTwoWeekRange":"7.285 - 16.88","fiftyDayAverage":15.27,"twoHundredDayAverage":14.06,"beta":1.45,"enterpriseValue":1751600768,"forwardPE":14.2,"priceToBook":3.67,"priceToSales":6.87,"enterpriseToRevenue":5.87,"enterpriseToEbitda":11.39,"pegRatio":0,"ebitda":153712000,"ebitdaMargin":51.5,"freeCashflow":124632496,"operatingCashflow":166918000,"totalDebt":68640000,"debtToEquity":12.1,"currentRatio":5.55,"returnOnAssets":13.7,"returnOnEquity":65,"analystRating":"1.9 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":17,"targetHighPrice":21,"targetLowPrice":15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.4,"institutionHeldPercent":59.1,"sharesOutstanding":128601671,"floatShares":126239258,"sharesShort":8886775,"shortRatio":8.07,"shortPercentOfFloat":6.8,"epsTrailing":2.16,"epsForward":1.12,"revenuePerShare":2.25,"bookValue":4.34,"officers":[{"age":58,"name":"Mr. Kevin C. Tang","title":"Chairman & CEO"},{"age":43,"name":"Mr. Stephen P. Robertson","title":"Chief Legal Officer, Corporate Secretary & Chief Compliance Officer"},{"age":55,"name":"Mr. Peter S. Greenleaf M.B.A.","title":"Consultant"},{"age":62,"name":"Mr. Michael S. Hearne CPA","title":"Chief Financial Officer"},{"age":38,"name":"Mr. Ryan  Cole","title":"Chief Operating Officer"},{"age":49,"name":"Mr. Thomas  Wei","title":"Chief Scientific Officer"},{"age":66,"name":"Mr. Stewart M. Kroll","title":"Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"http://www.isotechnika.com/for_investors/","website":"https://www.auriniapharma.com","phone":"250 744 2487"}}